The EU AI Act has given life sciences companies more time on the most resource-intensive part of the regime. It has not permitted commercial teams to wait. On 29 June 2026, the Council of the European Union gave final approval to the Digital Omnibus on AI, part of the EU’s broader simplification agenda. The package…
The European MedTech launch model is not failing because clinicians stopped caring about innovation. It is failing because the buying system changed faster than the commercial operating model around it. When a European MedTech launch misses its number, the review usually lands on familiar explanations: pricing pressure, reimbursement delay, procurement friction, competitor response, or slower-than-expected…
Week of 8–14 June 2026 This was a week about the price of proof. GSK paid a premium for late-stage oncology assets already under FDA review. Roche put serious money behind a validated target through a newer modality. Europe’s medicines regulators made reliability the centre of the AI conversation. The UK edged closer to a…
Week of 27 April–3 May 2026 Europe had a useful reality check this week. The strongest signals did not come from glossy AI claims, minor partnerships dressed up as strategy, or another ceremonial innovation slogan. They came from the machinery beneath growth: pricing, launch sequencing, regulatory support, evidence expectations, operating-model discipline, and whether Europe can…
Week of 30 March–5 April 2026 (#31) This was a week of infrastructure hiding in plain sight. A sovereign-cloud launch, a large rare-disease acquisition, EU funding for generative-AI cancer research, and a cluster of regulatory deadlines all pointed to the same underlying shift: life sciences is moving from digital ambition to execution architecture. Commercial Moves…